Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 6, 2016, Pages

  Fullerton, Birgit ^a   Siebenhofer, Andrea ^a   Jeitler, Klaus ^b   Horvath, Karl ^b   Semlitsch, Thomas ^b   Berghold, Andrea ^b   Plank, Johannes ^b   Pieber, Thomas R ^b   Gerlach, Ferdinand M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; INSULIN; INSULIN LISPRO;

ADULT; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; META ANALYSIS;

ADULT; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN LISPRO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84977606171     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012161     Document Type: Review

References (144)

1. Ferguson SC, Strachan MWJ, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes/Metabolism Research and Reviews 2001;17(4):285-91. [MEDLINE: 66]
2. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
3. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetic Medicine 2003;20:626-34.
4. Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Research and Clinical Practice 2006;71(2):131-39.
5. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2000;17(11):762-70. [MEDLINE: 112]
6. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
7. Iwamoto Y, Akanuma Y, Niimi H, Sasaki N, Tajima N, Kawamori R, et al. Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients treated with basal-bolus insulin therapy - Phase III clinical trial in Japan. Journal of the Japan Diabetes Society 2001;44(10):799-811.
8. Provenzano C, Vero R, Oliva A, Leto G, Puccio L, Vecci E, et al. Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. Diabetes, Nutrition & Metabolism 2001;14(3):133-9. [MEDLINE: 82]
9. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
10. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000;23(5):583-8. [MEDLINE: 149]
11. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, accessed 29 January 2016.
12. Recasens M, Aguilera E, Morinigo R, Casamitjana R, Nicoletti F, Gomis R, et al. Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving β-cell function at onset of type 1 diabetes mellitus. Diabetes Research and Clinical Practice 2003;60:153-9.
13. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics 1997;19(1):62-72.
14. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs humulin insulin treatment in young subjects with type 1 diabetes. Diabetic Medicine 1996;13(1):47-52. [MEDLINE: 579]
15. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
16. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics 1997;19(1):62-72.
17. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs humulin insulin treatment in young subjects with type 1 diabetes. Diabetic Medicine 1996;13(1):47-52. [MEDLINE: 579]
18. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf (accessed 29 January 2016).
19. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabetic Medicine 1996;13(1):47-52.
20. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
21. Altuntas Y, Ozen B, Ozturk B, Sengul A, Ucak S, Ersoy O, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes, Obesity & Metabolism 2003;5(6):371-8.
22. Bastyr III EJ, Huang Y, Brunelle RL, Vignati L, Cox DJ, Kotsanos JG. Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. Diabetes Obesity and Metabolism 2000;2(1):39-46.
23. Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, et al. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients. Chinese Medical Journal 2007;120(19):1700-3.
24. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. European Journal of Internal Medicine 2004;15(8):496-502.
25. Boivin S, Belicar P, Melki V. Assessment of in vivo stability of a new insulin preparation for implantable insulin pumps. A randomized multicenter prospective trial. Diabetes Care 1999;22(12):2089-90.
26. Caixàs A, Pérez A, Payés A, Otal C, Carreras G, Ordóñez-Llanos J, et al. Effects of a short-acting insulin analog (Insulin Lispro) versus regular insulin on lipid metabolism in insulin-dependent diabetes mellitus. Metabolism: Clinical & Experimental 1998;47(4):371-6.
27. Chan WB, Chow CC, Yeung VT, Chan JC, So WY, Cockram CS. Effect of insulin lispro on glycaemic control in Chinese diabetic patients receiving twice-daily regimens of insulin. Chinese Medical Journal 2004;117(9):1404-7.
28. Chen SF, Li H. Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system [Chinese]. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih Chinese Journal of Epidemiology 2011;32(8):827-9.
29. Chlup R, Zapletalová J, Seckar P, Chlupová L, Táncosová S, Reznícková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump. Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, Czech Republic 2004;148(1):27-32.
30. Cypryk K, Sobczak M, Petynska-Marczewska M, Zawodniak-Szalapska M, Szymczak W, Wilczynski J, et al. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2004;10(2):29-32.
31. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27(10):2363-8.
32. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996;45(12):1750-4.
33. Gao Y, Pan CY, Zou DJ, Xu ZR, Liu XM, Guo XH. Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics [Chinese]. Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2009;89(28):1960-3.
34. Garg SK, Anderson JH, Gerard LA, Mackenzie TA, Gottlieb PA, Jennings MK, et al. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obesity and Metabolism 2000;2(5):307-11. [MEDLINE: 842]
35. Gram J, Henriksen JE, Grodum E, Juhl H, Hansen TB, Christiansen C, et al. Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 2011;34(1):27-33.
36. Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A. Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Experimental & Clinical Endocrinology & Diabetes 2013;121(4):210-3.
37. Holleman F, Schmitt H, Symanowski S, Rees A, Rottiers R, Anderson J. Pre-meal therapy with lispro insulin and regular insulin in IDDM patients. The Netherlands Journal of Medicine 1997;50(5):A20-1.
38. Iwamoto Y. An open-labelled, randomised, parallel group, multicentre, safety and efficacy study of NN-X14Mix50 (BIAsp50) in a twice daily regimen in type 2 diabetic subjects, 2002. novonordisk-trials.com/website/pdf/registry/bin_20080410-024437-672.pdf (last accessed 25 June 2015).
39. Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004;27(11):2739-40.
40. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999;22(3):468-77.
41. Laube H, Heller M, Liersch J, Mäser E, Linn Th. Experience with lispro-insulin in the intensified therapy of IDDM and NIDDM patients. Diabetes und Stoffwechsel 1996;5(6):273-6.
42. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 1999;22(5):801-5.
43. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25(5):876-82.
44. Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003;26(4):1193-8.
45. Pérez-Maraver M, Caballero-Corchuelo J, Boltana A, Insa R, Soler J, Montanya E. Comparison of human insulin and insulin analogues on hypoglycaemia and metabolic variability in type 1 diabetes using standardized measurements (HYPO score and Lability Index). Acta Diabetologica 2013;50(4):529-35.
46. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, et al. Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabetic Medicine 2005;22(5):606-11.
47. Persson B, Swahn ML, Hjertberg R, Hanson U, Nord E, Nordlander E, et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Research & Clinical Practice 2002;58(2):115-21.
48. Pfützner A, Forst T, Mitri M, Löffler A, Heise J, Forkel C, et al. Impact of short-acting insulin analogs on biomarkers of oxidative stress and chronic systemic inflammation in patients with type 2 diabetes: results from a pilot study. Diabetes. 2013; Vol. 62 Suppl:A235-6.
49. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. European Journal of Pediatrics 1997;156(11):838-40.
50. Rayman G, Profozic V, Middle M. Insulin glulisine imparts effective glycaemic control in patients with type 2 diabetes. Diabetes Research & Clinical Practice 2007;76(2):304-12.
51. Roach P, Strack T, Arora V, Zhao Z. Improved glycemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. International Journal of Clinical Practice 2001;55(3):177-82.
52. Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clinical & Investigative Medicine - Medecine Clinique et Experimentale 2001;24(6):292-8.
53. Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G. Metabolic control in patients with type 2 diabetes using humalog mix 50 injected three times daily: crossover comparison with human insulin 30/70. Hormone and Metabolic Research 2004;36(3):188-93.
54. Skrha J, Smahelova A, Andol M, Vrtovec M, Subić J, Kreze A, et al. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus. Sbornik Lekarsky 2002;103(1):15-21.
55. Tubiana-Rufi N, Munz-Licha G. Lispro analog and quality of life. Diabetes & Metabolism 1997;3:58-62.
56. Vignati L, Anderson JH Jr, Iversen PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin dependent diabetes. Clinical Therapeutics 1997;19(6):1408-21.
57. Yanagisawa K, Yamagishi S, Ashihara J, Obara S, Wada N. Evaluation of efficacy, safety and QoL of glulisine on Japanese type 1 diabetes. Diabetes 2013;62 Suppl:A654.
58. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22(Suppl 1):S5-19.
59. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(Suppl 1):S12-54. [PUBMED: 18165335]
60. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clinical Therapeutics 1997;19(1):62-72.
61. Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, et al. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutrition, Metabolism, and Cardiovascular Diseases 2001;11:168-75.
62. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabetic Medicine 2006;23:285-92.
63. Banerjee S, Tran K, Li H, Cimon K, Daneman D, Simpson S, et al. Short-Acting Insulin Analogues for Diabetes Mellitus: Meta-analysis of Clinical Outcomes and Assessment of Cost Effectiveness (Technology Report No. 87). Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007.
64. Becker MP, Balagtas CC. Marginal modeling of binary cross-over data. Biometrics 1993;49:997-1009.
65. Berger M, Jörgens V. Insulintherapie in der Praxis. Berlin, Heidelberg: Springer Verlag, 2001.
66. Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 2002;25(3):439-44.
67. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabetic Medicine 2003;20:626-34.
68. Bradley C, Lewis KS. Measures of psychological well-being and treatment satisfaction developed from the responses of people with tablet-treated diabetes. Diabetic Medicine 1990;7(5):445-51.
69. Brunelle RL, Llewelyn J, Anderson JH Jr, Gale EAM, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998;21(10):1726-31.
70. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabetic Medicine 2000;17(5):371-5.
71. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180(4):400-7.
72. Cohen 2011. The prickly problem of access to insulin. BMJ 2011;343:d5782.
73. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabetic Medicine 2003;20:863-6.
74. Curtin F, Altman DG, Elbourne DR. Meta-analysis combining parallel and cross-over clinical trials II: binary outcomes. Statistics in Medicine 2002;21:2145-59.
75. Davidson MB. Insulin analogs - is there a compelling case to use them? No!. Diabetes Care 2014;37(6):1771-74.
76. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329:977-86.
77. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289(17):2254-64.
78. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
79. European Medicines Agency. Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus, 2002. www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003262.pdf (accessed 14 April 2016).
80. Engwerda EE, Abbink EJ, Tack C J, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011;34(8):1804-8.
81. Frick M, Knollmeyer J, Riederer H, Heinemann C. Modern insulins - comment on facts and assumptions in a recent Editorial. Diabetologia 2008;51(4):689-91.
82. Gale, EAM . Commentary: politics of affordable insulin. BMJ 2011;343:d5675.
83. Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK, et al. Pre-meal insulin analogue insulin lispro vs humulin insulin treatment in young subjects with type 1 diabetes. Diabetic Medicine 1996;13(1):47-52. [MEDLINE: 579]
84. Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in basal-bolus regimens in type 1 diabetes mellitus. Endocrine Practice 2010;16(3):486-505.
85. Gerstein HC, Haynes RB. Evidence-Based Diabetes Care. Hamilton: BC Decker Inc, 2001.
86. Gough SC. A review of human and analogue insulin trials. Diabetes Research and Clinical Practice 2007;77(11):1-15.
87. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufrikha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993;36:282-91.
88. Grunberger G. Insulin analogs - are they worth it? Yes!. Diabetes Care 2014;37(6):1767-70.
89. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Reviews 1998;19(5):583-92.
90. Heinemann L, Kapitza C, Starke AAR, Heise T. Time-action profile of the insulin analogue B28Asp. Diabetic Medicine 1996;13:683-4.
91. Heise T, Haahr H, Jensen L, Erichsen L, Hompesch M. Faster-acting insulin aspart improves postprandial glycaemia versus insulin aspart in patients with type 1 diabetes mellitus. Diabetes 2014;63(Suppl 1):A34.
92. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. Journal of Diabetes 2013;5:482-91.
93. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47(4):622-29.
94. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
95. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
96. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2009;172(1):137-59.
97. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
98. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
99. Holden SE, Poole CD, Morgan CL, Currie CJ. Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open 2011;1(2):e000258.
100. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1997;20(12):1827-32.
101. Holleman F, Gale EAM. Nice insulins, pity about the evidence. Diabetologia 2007;50:1783-90.
102. Home, PD . The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism 2012;14(9):780-88.
103. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402.
104. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201-11.
105. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Short acting insulin analogues for the treatment of type 1 diabetes mellitus, 2007. www.iqwig.de/download/A05-02_Abschlussbericht_Kurzwirksame_Insulinanaloga_bei_Diabetes_mellitus_Typ_1.pdf. Köln, (accessed 29 January 2016).
106. Johansson UB, Adamson UCK, Lins PES, Wredling RAM. Improved blood glucose variability, HbA1c Insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish multicenter lispro insulin study. Diabetes Metabolism 2000;26(3):192-6.
107. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 2013;56(11):2392-400.
108. Jørgensen LN, Didriksen LH, Drejer K. Carciogenic effect of the human insulin analogue B10 Asp in female rats. Diabetologia 1992;35 Suppl 1:A3.
109. Kaye J, Krasner A, Canney L, Pichotta P, Simms P, Krishnarajah J, et al. Novel formulations BIOD-238 and BIOD-250 result in more rapid absorption and declines from peak than Humalog. Proceeding of the 49th Annual Meeting of the European Association for the Study of Diabetes; 2013 Sept 23-27; Barcelona. Barcelona, Spain: EASD, 2013:56 S413.
110. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. Journal of Clinical Investigation 1985;75:1028-36.
111. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365]
112. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. Journal of Diabetes Science and Technology 2012;6(4):786-96.
113. Kurtzhals P, Schäffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlation of receptor binding and metabolic and metogenic potencies of insulin analogues designed for clinical use. Diabetes 2000;49:999-1005.
114. Landau Z, Klonoff D, Nayberg I, Feldman D, Levit SB, Lender D, et al. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. Diabetes/Metabolism Research and Reviews 2014;30(8):686-92.
115. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine 2009;6(7):1-28. [DOI: 10.1371/journal.pmed.1000100]
116. Marshall SM, Home PD, Rizza RA. The Diabetes Annual 12. Amsterdam: Elsevier Science Ltd, 1999.
117. Mosekilde E, Skovbo JK, Binder C, Pramming S, Thorsteinsson B. Modeling absorption kinetics of subcutaneous injected soluble insulin. Journal of Pharmacokinetics and Biopharmaceutics 1989;17(1):67-87.
118. Muehlhauser I, Overmann H, Bender R, Bott U, Berger M. Risk factors of severe hypoglycaemia in adult patients with type 1 diabetes - a prospective population based study. Diabetologia 1998;41:1274-82.
119. Müller N, Frank T, Kloos C, Lehmann T, Wolf G, Müller UA. Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type 2 diabetes and human insulin. Diabetes Care 2013;36:1865-69.
120. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
121. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Research and Clinical Practice 1999;43:137-42.
122. Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Norgaard K, Perrild H, Christiansen JS, et al. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. The Lancet Diabetes & Endocrinology 2014;2(7):S84.
123. Pfützner A, Dissel S, Forkel C, Grenningloh M, Bitton G, Nagar R, et al. Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control. Current Medical Research & Opinion 2014;30(10):2001-8.
124. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes/Metabolism Research and Reviews 2015;32(1):21-39. [DOI: 10.1002/dmrr.2653]
125. Renner R, Pfützner A, Trautmann ME, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Diabetes Care 1999;22(5):784-8.
126. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:d549.
127. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes, Obesity and Metabolism 2007;9(6):799-812.
128. Rys P, Pankiewicz O, Łach K, Kwaskowski A, Skrzekowska-Baran I, Malecki MT. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes & Metabolism 2011;37(3):190-200.
129. Sawicki PT. Commentary: does additional benefit justify additional costs of insulin analogues?. BMJ 2011;343:d5858.
130. Scheen AJ, Letiexhe MR, Lefebvre PJ. Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes & Metabolism 1999;25(2):157-62.
131. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care 1998;21(4):570-3.
132. Sciacca L, Le Moli R, Vigneri R. Insulin analogs and cancer. Frontiers in Endocrinology 2012;3:21. [DOI: 10.3389/fendo.2012.00021]
133. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin inpatients with diabetes mellitus. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003287.pub4]
134. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180(4):385-97.
135. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009;52(9):1699-708.
136. Stedman MR, Curtin F, Elbourne DR, Kesselheim AS, Brookhart MA. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2009;40(6):1732-4.
137. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
138. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vicenzo A, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994;37(7):713-20.
139. World Health Organization Expert Committee on Diabetes Mellitus. Second report. WHO Technical Report Series 1980; Vol. No. 646.
140. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-53.
141. World Health Organization. 18th Expert Committee on the Selection and Use of Essential Medicines. Review of the evidence comparing insulin (human or animal) with analogue insulins; 2011 Mar 21-25; Accra, Ghana. 2011.
142. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.
143. Zinman B. The physiological replacement of insulin: an elusive goal. New England Journal of Medicine 1989;321(6):363-70.
144. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46(3):440-3.